drugset / Trial / NCT04685993

A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial

NCT04685993

Phase 2 Completed 25 enrolled Lipocine Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label extension to Study LPCN 1144-18-002. The study is aimed at evaluating the safety and tolerability of LPCN 1144 in adult men with NASH.

Timeline

Start
2020-11-11
Primary completion
2022-03-01
Completion
2022-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Undecanoate Small molecule 225 mg Oral